Optimal pretreatment timing for high load dosing (600 mg) of clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectiveness

International Journal of Cardiology

Volumn 144, Issue 2, 2010, Pages 255-257

  Motovska, Zuzana ^a,b   Widimsky, Petr ^a,b   Petr, Robert ^a,b   Bilkova, Dana ^a,b   Marinov, Iuri ^c   Simek, Stanislav ^a,d   Kala, Petr ^e,f  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

^e MASARYK UNIVERSITY   (Czech Republic)

^f UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Clopidogrel; Elective coronary angiography; Pretreatment

Indexed keywords

CLOPIDOGREL; PURINERGIC P2Y12 RECEPTOR; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; HEART CATHETERIZATION; HUMAN; LETTER; LOADING DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SINGLE DRUG DOSE; THROMBOCYTE ACTIVATION; TIME; TREATMENT PLANNING;

EID: 77957827894     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2009.01.017     Document Type: Article

References (9)

1. P. Widimsky, Z. Motovska, and S. Simek Clopidogrel pretreatment for all patients > 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicenter trial PRAGUE-8 Eur Heart J Apr 25 2008 [Electronic publication ahead of print]
2. J. Geiger, L. Teichmann, and R. Grossmann Monitoring of clopidogrel action: comparison of methods Clin Chem 51 6 2005 957 965
3. S.R. Steinhubl, P.B. Berger, and J.T. Mann III Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial JAMA 288 19 Nov 20 2002 2411 2420
4. G. Montalescot, G. Sideris, and C. Meuleman A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial J Am Coll Cardiol. 48 5 Sep 5 2006 931 938
5. E. Braunwald, D. Angiolillo, and E. Bates Assessing the current role of platelet function testing Clin Cardiol. 31 S1 Mar 2008 I10 I16
6. L. Bonello, L. Camoin-Jau, and S. Arques Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study J Am Coll Cardiol. 51 14 2008 Apr 8 1404 1411
7. L. Bonello, F. Paganelli, and M. Arpin-Bornet Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events J Thromb Haemost 5 2007 1630 1636
8. K.A. Fox, S.R. Mehta, and R. Peters Clopidogrel in unstable angina to prevent recurrent ischemic events trial. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) trial Circulation 110 10 2004 1202 1208
9. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150